A Phase IIIB, randomized, open-label, multicenter clinical trial to assess the immunogenicity and safety of GSK Biologicals' Herpes Zoster vaccine GSK1437173A when co-administered with Prevenar13 in adults aged 50 years and older.
Latest Information Update: 30 Aug 2023
At a glance
- Drugs GSK 137173A (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate
- Indications Herpes zoster
- Focus Pharmacodynamics; Registrational
- Sponsors GlaxoSmithKline Biologicals; GSK
- 25 Dec 2021 Primary endpoint (Anti-pneumococcal antibody titers) has been met, as per results published in the Journal of Infection
- 25 Dec 2021 Primary endpoint (Anti-gE antibody concentrations) has been met, as per results published in the Journal of Infection
- 25 Dec 2021 Primary endpoint (Number of subjects with a vaccine response) has been met, as per results published in the Journal of Infection